Loading…
Pharvaris N.V. is projected to rise to $47.38 by 2027, a +40% move from its current price of $33.88. PHVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $33.15 | $33.90 | $34.67 | +0.07% |
| Aug 2 | $32.87 | $33.93 | $35.02 | +0.14% |
| Aug 3 | $32.66 | $33.95 | $35.30 | +0.21% |
| Aug 4 | $32.49 | $33.98 | $35.53 | +0.28% |
| Aug 5 | $32.34 | $34.00 | $35.75 | +0.35% |
| Aug 6 | $32.21 | $34.02 | $35.94 | +0.43% |
| Aug 7 | $32.09 | $34.05 | $36.13 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.09 | $34.05 | $36.13 | +0.50% |
| Week 2 | $31.46 | $34.22 | $37.21 | +1.00% |
| Week 3 | $31.03 | $34.39 | $38.11 | +1.50% |
| Week 4 | $30.69 | $34.56 | $38.91 | +2.00% |
| Week 5 | $30.42 | $34.73 | $39.66 | +2.51% |
| Week 6 | $30.18 | $34.90 | $40.36 | +3.02% |
| Week 7 | $29.98 | $35.08 | $41.04 | +3.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V. is a biopharmaceutical company focused on rare diseases with unmet needs. The stock currently trades at $33.88 per share and has a market capitalization of $2.37B. It is ranked 1799 by market capitalization among publicly traded securities.
The asset sits in the Healthcare category with a focus on bradykinin-mediated conditions and orphan diseases. The current price provides a view into near-term performance, while the market cap and rank reflect its size within the broader market landscape.
Forecasts imply a path of rising averages and upside potential over the coming years, with 2027 and beyond showing bullish signals and meaningful increases in expected value.
A major floor 25.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 6.1% above — a clean break opens room to run.
A major ceiling 10.7% above — clearing it would confirm fresh momentum.
Key PHVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.66 | Buy | $33.61 | Buy |
| MA 10 | $33.88 | Sell | $33.81 | Buy |
| MA 20 | $34.29 | Sell | $33.85 | Buy |
| MA 50 | $32.63 | Buy | $32.79 | Buy |
| MA 100 | $30.47 | Buy | $31.04 | Buy |
| MA 200 | $27.91 | Buy | $28.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.08 | Neutral |
| Stoch RSI (14) | 38.56 | Neutral |
| CCI (20) | -38.65 | Neutral |
| Williams %R (14) | -50.39 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | -1.57 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 49.61 | Neutral |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 45.61 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 33.26 | Buy |
| ADX (14) | 12.33 | Neutral |
| ATR (14) | 0.75 | Info |
The near-term technical picture is bullish. The sentiment is BULLISH, while the RSI14 sits at 50, indicating a neutral momentum reading.
The stock trades above the 50-day moving average of $32.63 and remains above the 200-day moving average of $27.91, suggesting constructive price action. Key levels to watch are support at $32.62 and resistance at $35.96, which frame the short-term trading range.
Over the last 30 days, price has fluctuated between $29.23 and $39.28, reflecting notable volatility as investors gauge near-term catalysts and sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.05 | $33.88 | $44.99 | 0% | Neutral | |
| $38.40 | $47.38 | $61.42 | +40% | Bullish | |
| $46.32 | $58.47 | $78.22 | +73% | Bullish | |
| $56.37 | $72.50 | $99.42 | +114% | Bullish | |
| $60.34 | $78.89 | $110.46 | +133% | Bullish | |
| $64.09 | $85.04 | $121.27 | +151% | Bullish | |
| $75.63 | $101.74 | $147.47 | +200% | Bullish | |
| $81.26 | $110.73 | $162.91 | +227% | Bullish | |
| $95.39 | $131.58 | $196.26 | +288% | Bullish | |
| $115.62 | $161.35 | $243.75 | +376% | Bullish | |
| $162.26 | $238.55 | $380.22 | +604% | Bullish | |
| $347.89 | $558.40 | $962.99 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $24.05 | $33.88 | $39.49 | +0.00% |
| August 2026 | $30.01 | $35.09 | $41.89 | +3.58% |
| September 2026 | $30.70 | $36.14 | $43.62 | +2.98% |
| October 2026 | $30.17 | $35.72 | $43.49 | -1.17% |
| November 2026 | $29.85 | $35.49 | $43.52 | -0.64% |
| December 2026 | $30.54 | $36.46 | $44.99 | +2.73% |
Click any year to see its month-by-month PHVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PHVS is projected to trade between $24.05 and $44.99, averaging $33.88 — a potential gain of 0% from today's $33.88. Price action looks broadly range-bound.
Pharvaris N.V.'s 2027 outlook centres on $47.38, within a $38.40 to $61.42 range. That is up +40% on the projected 2026 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, PHVS could reach as high as $78.22, with a base case around $58.47 and support toward $46.32 — roughly +73% from $33.88. Momentum favours further upside here.
Expect PHVS to range from $56.37 to $99.42 through 2029. The $72.50 average target implies a +114% move from current prices. That is up +24% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PHVS price prediction for 2030 points to an average of $78.89 (low $60.34, high $110.46) — a potential gain of +133% on today's $33.88. Momentum favours further upside here.
In 2031, PHVS is projected to trade between $64.09 and $121.27, averaging $85.04 — a potential gain of +151% from today's $33.88. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Pharvaris N.V.'s 2032 outlook centres on $101.74, within a $75.63 to $147.47 range. That is up +20% on the projected 2031 average. That marks a +200% change versus current levels. Momentum favours further upside here.
By 2033, PHVS could reach as high as $162.91, with a base case around $110.73 and support toward $81.26 — roughly +227% from $33.88. Buyers look set to stay in control over this stretch.
Expect PHVS to range from $95.39 to $196.26 through 2034. The $131.58 average target implies a +288% move from current prices. That is up +19% on the projected 2033 average. Momentum favours further upside here.
The PHVS price prediction for 2035 points to an average of $161.35 (low $115.62, high $243.75) — a potential gain of +376% on today's $33.88. Buyers look set to stay in control over this stretch.
In 2040, PHVS is projected to trade between $162.26 and $380.22, averaging $238.55 — a potential gain of +604% from today's $33.88. That is up +48% on the projected 2035 average. Momentum favours further upside here.
Pharvaris N.V.'s 2050 outlook centres on $558.40, within a $347.89 to $962.99 range. That is up +134% on the projected 2040 average. That marks a +15.5x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHVS today (≈ 29.515939 PHVS) could be worth
$16,481.75
+$15,481.75 (+1548%) by 2050 · US Dollar
Based on the average projected PHVS price of $558.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHVSwould be worth at today's price.
$1,000 invested in PHVS on Jul 30, 2025 (≈ 50.530569 PHVS) would be worth
$1,711.98
+$711.98 (+71.2%) today · 1.71× · US Dollar
Based on a PHVS entry price of $19.79 vs. today's $33.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $33.26 | $1,018.64 | +1.9% |
| 1 month ago | $34.58 | $979.76 | -2.0% |
| 3 months ago | $29.44 | $1,150.82 | +15.1% |
| 6 months ago | $27.05 | $1,252.5 | +25.2% |
| 1 year ago | $19.79 | $1,711.98 | +71.2% |
| All time (5.0y) ago | $16.49 | $2,054.58 | +105.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHVS forecast.
Our base-case forecast reaches $68.00 around 2029.
Implied market cap at $68.00: $4.75B
The multi-year forecast shows substantial upside potential from the current level. The 2026 forecast indicates an average price of $33.88 with a min of $24.05 and a max of $44.99, with a neutral sentiment and an ROI of 0.
From 2027 onward, the outlook turns more bullish, with the 2027 average $47.38, a min $38.40, a max $61.42, and an ROI of 39.9.
The projection continues to rise in 2028 (avg $58.47, min $46.32, max $78.22, ROI 72.6) and in 2029 (avg $72.50, min $56.37, max $99.42, ROI 114). By 2030, the average is $78.89 with a min $60.34 and a max $110.46, and an ROI of 132.8, maintaining a bullish stance.
Beyond 2030, forecasts extend to 2040 (avg $238.55, min $162.26, max $380.22, ROI 604.1) and 2050 (avg $558.40, min $347.89, max $962.99, ROI 1548.2), both labeled bullish. These projections imply meaningful upside over the longer term, but they are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $78.89 with a min of $60.34 and a max of $110.46, and an ROI of 132.8; sentiment is BULLISH.
Forecasts show a bullish sentiment from 2027 onward with rising averages (e.g., 2027 average $47.38) and rising ROIs (e.g., 2030 ROI 132.8). These are estimates and not guarantees.
Yes. The 2030 forecast max is $110.46, indicating a potential above-$100 level in that year (2030), while 2029 max is $99.42.
The 30-day range is from $29.23 to $39.28.
Current price is $33.88 and market capitalization is $2.37B.
Pharvaris N.V. Community Discussion
0Share your Pharvaris N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.